Immedica Pharma Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Immedica Pharma's estimated annual revenue is currently $28.1M per year.(i)
  • Immedica Pharma's estimated revenue per employee is $201,000

Employee Data

  • Immedica Pharma has 140 Employees.(i)
  • Immedica Pharma grew their employee count by 27% last year.

Immedica Pharma's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
Head Accounting and ReportingReveal Email/Phone
3
Head Specialty CareReveal Email/Phone
4
Head Northern & Southern EuropeReveal Email/Phone
5
General CounselReveal Email/Phone
6
Head RegulatoryReveal Email/Phone
7
Head QualityReveal Email/Phone
8
Regional Director / General Manager UK & IrelandReveal Email/Phone
9
Global Brand Director Genetic & Metabolic PortfolioReveal Email/Phone
10
Regional Director, Head MENA& TurkeyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$17.1M85-21%N/AN/A
#2
$99.7M49622%N/AN/A
#3
$22.9M114-67%N/AN/A
#4
$27.3M1367%N/AN/A
#5
$20.9M10428%N/AN/A
#6
$103.1M5134%N/AN/A
#7
$9.4M472%N/AN/A
#8
$2.4M12-20%N/AN/A
#9
$28.1M14027%N/AN/A
#10
$5M254%N/AN/A
Add Company

What Is Immedica Pharma?

About Immedica Pharma Immedica is a fast-growing private niche pharma group. Its headquarter is based in Stockholm, Sweden, and it has commercial coverage across Europe and the Middle East. Immedica provides significant know-how and experience from commercialization of niche/specialty care products across Europe and the Middle East, and the company's management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality and product distribution. Immedica's main owner is Impilo AB, a private Nordic investment company established in 2017, with more than SEK 3.6 billion in committed capital from leading Nordic and international investors. More information is available at www.immedica.com

keywords:N/A

N/A

Total Funding

140

Number of Employees

$28.1M

Revenue (est)

27%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Immedica Pharma News

2022-04-06 - Actinium Pharmaceuticals, Inc. and Immedica Announce ...

Immedica is a fast-growing private niche pharma group with its headquarter in Stockholm, Sweden, and commercial coverage across Europe and the...

2022-04-06 - Actinium gains on agreement with Immedica Pharma for conditioning agent

Clinical-stage biotech Actinium Pharmaceuticals (NYSE:ATNM) and Swedish pharma group, Immedica Pharma AB announced an agreement for Iomab-B,...

2022-04-06 - Actinium Pharmaceuticals Up 20% After Commercialization Agreement

Actinium Pharmaceuticals Inc. shares were 20% higher to $6.33 ... in a commercialization agreement with Immedica Pharma AB for Iomab-B for...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22.3M14017%N/A
#2
$34.6M14322%N/A
#3
N/A1446%N/A
#4
$22.3M1445%N/A
#5
$26M14525%N/A